Freeline Therapeutics Holdings plc stock is down -5.33% since 30 days ago. The next earnings date is Dec 15, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November. 0% of analysts rate it a buy.
Freeline Therapeutics Holdings plc develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.